ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Targeting Seipin to Alleviate Hepatic Steatosis in Zebrafish (Danio Rerio).
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fetuin-b Mediates Lipid Overload-Induced Hepatic Lipid Accumulation in Large Yellow Croaker (Larimichthys crocea).FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Targeting Seipin to Alleviate Hepatic Steatosis in Zebrafish (Danio Rerio).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Loss of Seipin causes the absence of whole-body adipose but abnormal liver lipid deposition in patients, and liver expression of Seipin is decreased in mice fed a high-fat diet (HFD). However, the underlying mechanism of Seipin-regulated liver lipid metabolism remains mysterious. Here, experiments show that over-expression of Seipin down-regulates HFD-induced liver triglyceride (TG) accumulation and promotes zebrafish growth. Real-time PCR and immunoblotting suggest that Seipin interacts with Plin2 through its second transmembrane domain to inhibit the expression of Plin2 by promoting Plin2 ubiquitination, thereby ameliorating lipid accumulation. Co-immunoprecipitation (CoIP) experiments and Biomolecular fluorescence complementation (BiFC) analysis reveal a close interaction between Seipin and phosphatidylcholine (PC) synthesis enzyme CCTα and CHPT in zebrafish and mice. Thus, Seipin may participate in PC synthesis and increase cellular PC levels. Elevated PC levels subsequently suppress Plin2 expression. Meanwhile, CCTα, the rate-limiting enzyme of the PC synthesis pathway, exhibited a unique regulatory role on Plin2 expression as a potential transcription factor. It is proposed that Seipin balances TG homeostasis, PC synthesis, and Plin2 expression to alleviate hepatic steatosis, providing a promising target for fatty liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.